Phase 2 N=30 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Kidney Cancer
Primary: Response to Sunitinib Therapy — 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
Healthy
Primary: Peak Plasma Concentration of d-Methylphenidate — 0.00; 15.06; 25.34; 20.34 mg/L
Phase 3 N=270 Evaluation of an Investigational Multi-Purpose Solution (MPS)
Study Focus is Healthy Contact Lens Wearers
Primary: Mean Lens Cleanliness as Measured by Light Reflectance — 65.5; 66.8 light reflectance score
Phase 2 N=30 Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Clinical Complete Response Rate at the Primary Tumor — 16 participants
N/A N=49 The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects
Dry Eye
Primary: Mean Change From Baseline in NITFBUT at Day 30 — 2.83; 0.66 seconds
N/A N=46 Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes
Diabetes · Insulin
Primary: Change in Weekly Mean Blood Glucose From Week 4 to Week 16 — 4.6; 8.1; 29.5 mg/dL
Phase 2 N=112 Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
Chronic Hepatitis C
Primary: Sustained Virologic Response (HCV RNA Below Lower Limit of Detection) — 32; 13; 43; 24 participants
Phase 2 N=64 Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (HCV RNA Below Lower Limit of Detection) — 3; 0; 39; 22 participants
Phase 3 N=278 A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Hypertension
Primary: Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)…
N/A N=60 Combining a Smoke Ending Aid With Behavioral Treatment - 1
Tobacco Use Disorder
Primary: Abstinence Rate — 3; 4 participants
N/A N=15 Factors Controlling the Formation of Salivary Films
Healthy
Primary: Impact of Ingredients on Thickness (Depth, nm) of Salivary Films Adsorbed Onto Solid Surfaces — 27 nm
Phase 3 N=400 Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
Schizophrenia · Schizophrenic Disorders · Psychotic Disorders
Primary: The Number of Participants Who Experienced Adverse Events as a Measure of Safety and Tolerability — 32; 88; 221; 341 Number of Participants
N/A N=124 Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
Type 2 Diabetes
Primary: Percentage Change in Hemoglobin A1c — -1.12; -0.82 percentage of HbA1c
Phase 2 N=54 Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
Severe Hypertriglyceridemia
Primary: AUC(0-t): Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (the Final Time With a Concentration ≥ LOQ) — 2650.1612; 661.9490 nmol.h/mL — p=<0.001
N/A N=202 Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population
Malignant Neoplasm of Large Intestine
Primary: Completion of a Colorectal Cancer Screening — 5; 31 participants